All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Adalimumab
Therapeutic Area: Dermatology Product Name: Humira
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2020
Details:
Approval is based on the data from a Japanese phase III clinical trial. The proportion of patients achieving at 100 of the target pyoderma gangrenosum ulcer area reduction at Week 26 of Humira administration was 54.5% in the trail.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sofpironium Bromide
Therapeutic Area: Dermatology Product Name: Ecclock
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Brickell Biotech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2020
Details:
Sofpironium bromide gel was deemed to be safe and well tolerated in this study, as well as in the accompanying 52-week long-term safety extension study in Japan. Japan is the first country to approve sofpironium bromide with commercial launch expected later this year.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
